Dr Mike Mitchell analyst at Panmure Gordon said this morning “This morning ImmuPharma has released prelims for the year-ending 31 December 2015. Today’s numbers reflect a business in development-phase – the pivotal phase III study for Lupuzor™ now having commenced – with the fund-raising process (£8.4m fundraising and EIS/VCT qualifying status) having been completed after the period-end. We currently have the stock Under Review, applied in light of the recent capital raise exercise, and following the announcement of today’s prelims we will be updating our forecasts imminently.”
Learning About Lupus
May is Lupus Awareness Month. It is a disease that is relatively common in the Caribbean yet many of us are unfamiliar with the condition. Lupus is an autoimmune condition that can affect almost every system